(CBT) Cabot - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US1270551013
Stock: Reinforcing Carbons, Specialty Carbons, Fumed Silica, Aerogel, Masterbatch
Total Rating 45
Risk 99
Buy Signal -0.66
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.37% |
| Yield on Cost 5y | 4.12% |
| Yield CAGR 5y | 5.81% |
| Payout Consistency | 90.7% |
| Payout Ratio | 25.3% |
| Risk 5d forecast | |
|---|---|
| Volatility | 33.3% |
| Relative Tail Risk | -10.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.38 |
| Alpha | -25.78 |
| Character TTM | |
|---|---|
| Beta | 0.796 |
| Beta Downside | 0.665 |
| Drawdowns 3y | |
|---|---|
| Max DD | 48.78% |
| CAGR/Max DD | 0.05 |
Description: CBT Cabot January 10, 2026
Cabot Corporation (NYSE: CBT) is a specialty chemicals and performance materials firm organized into two primary segments: Reinforcement Materials, which supplies carbon black for tire tread and industrial rubber products, and Performance Chemicals, which produces specialty carbons, fumed silica/alumina, aerogels, masterbatches, inkjet colorants, carbon nanotubes, and related additives for a broad range of downstream markets.
In FY 2023 Cabot generated roughly $2.8 billion in revenue, with the Reinforcement Materials segment contributing about 55 % and Performance Chemicals the remaining 45 %. The company’s EBITDA margin hovered near 13 %, reflecting relatively stable pricing power despite volatile raw-material costs (natural gas and oil). Key demand drivers include the accelerating rollout of electric vehicles-fueling higher consumption of fumed silica and alumina in lithium-ion batteries-and the long-term growth of global tire production, which underpins carbon-black sales. Conversely, cyclical automotive output and commodity price swings represent material headwinds.
For a data-rich, quantitative assessment of Cabot’s valuation sensitivities and peer benchmarks, a deeper dive on ValueRay can help you surface the metrics that matter most.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 311.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA -1.60 > 1.0 |
| NWC/Revenue: 16.16% < 20% (prev 18.78%; Δ -2.62% < -1%) |
| CFO/TA 0.18 > 3% & CFO 667.0m > Net Income 311.0m |
| Net Debt (896.0m) to EBITDA (773.0m): 1.16 < 3 |
| Current Ratio: 1.67 > 1.5 & < 3 |
| Outstanding Shares: last quarter (52.9m) vs 12m ago -3.82% < -2% |
| Gross Margin: 25.40% > 18% (prev 0.25%; Δ 2515 % > 0.5%) |
| Asset Turnover: 97.50% > 50% (prev 109.5%; Δ -12.00% > 0%) |
| Interest Coverage Ratio: 8.09 > 6 (EBITDA TTM 773.0m / Interest Expense TTM 76.0m) |
Altman Z'' 4.52
| A: 0.16 (Total Current Assets 1.46b - Total Current Liabilities 874.0m) / Total Assets 3.76b |
| B: 0.49 (Retained Earnings 1.84b / Total Assets 3.76b) |
| C: 0.17 (EBIT TTM 615.0m / Avg Total Assets 3.70b) |
| D: 0.75 (Book Value of Equity 1.52b / Total Liabilities 2.03b) |
| Altman-Z'' Score: 4.52 = AA |
Beneish M -3.23
| DSRI: 1.01 (Receivables 616.0m/677.0m, Revenue 3.61b/3.99b) |
| GMI: 0.97 (GM 25.40% / 24.75%) |
| AQI: 0.97 (AQ_t 0.16 / AQ_t-1 0.16) |
| SGI: 0.90 (Revenue 3.61b / 3.99b) |
| TATA: -0.09 (NI 311.0m - CFO 667.0m) / TA 3.76b) |
| Beneish M-Score: -3.23 (Cap -4..+1) = AA |
What is the price of CBT shares?
As of February 08, 2026, the stock is trading at USD 74.58 with a total of 502,398 shares traded.
Over the past week, the price has changed by +3.31%, over one month by +6.27%, over three months by +26.60% and over the past year by -13.10%.
Over the past week, the price has changed by +3.31%, over one month by +6.27%, over three months by +26.60% and over the past year by -13.10%.
Is CBT a buy, sell or hold?
Cabot has received a consensus analysts rating of 3.60.
Therefor, it is recommend to hold CBT.
- StrongBuy: 2
- Buy: 0
- Hold: 2
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the CBT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 70.8 | -5.1% |
| Analysts Target Price | 70.8 | -5.1% |
| ValueRay Target Price | 76.1 | 2.1% |
CBT Fundamental Data Overview February 05, 2026
P/E Trailing = 11.8422
P/E Forward = 10.9649
P/S = 1.0157
P/B = 2.4019
P/EG = 1.83
Revenue TTM = 3.61b USD
EBIT TTM = 615.0m USD
EBITDA TTM = 773.0m USD
Long Term Debt = 856.0m USD (from longTermDebt, last fiscal year)
Short Term Debt = 272.0m USD (from shortTermDebt, last quarter)
Debt = 1.13b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 896.0m USD (from netDebt column, last quarter)
Enterprise Value = 4.67b USD (3.77b + Debt 1.13b - CCE 230.0m)
Interest Coverage Ratio = 8.09 (Ebit TTM 615.0m / Interest Expense TTM 76.0m)
EV/FCF = 11.64x (Enterprise Value 4.67b / FCF TTM 401.0m)
FCF Yield = 8.59% (FCF TTM 401.0m / Enterprise Value 4.67b)
FCF Margin = 11.12% (FCF TTM 401.0m / Revenue TTM 3.61b)
Net Margin = 8.62% (Net Income TTM 311.0m / Revenue TTM 3.61b)
Gross Margin = 25.40% ((Revenue TTM 3.61b - Cost of Revenue TTM 2.69b) / Revenue TTM)
Gross Margin QoQ = 24.85% (prev 24.47%)
Tobins Q-Ratio = 1.24 (Enterprise Value 4.67b / Total Assets 3.76b)
Interest Expense / Debt = 1.60% (Interest Expense 18.0m / Debt 1.13b)
Taxrate = 31.09% (37.0m / 119.0m)
NOPAT = 423.8m (EBIT 615.0m * (1 - 31.09%))
Current Ratio = 1.67 (Total Current Assets 1.46b / Total Current Liabilities 874.0m)
Debt / Equity = 0.71 (Debt 1.13b / totalStockholderEquity, last quarter 1.57b)
Debt / EBITDA = 1.16 (Net Debt 896.0m / EBITDA 773.0m)
Debt / FCF = 2.23 (Net Debt 896.0m / FCF TTM 401.0m)
Total Stockholder Equity = 1.52b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.41% (Net Income 311.0m / Total Assets 3.76b)
RoE = 20.45% (Net Income TTM 311.0m / Total Stockholder Equity 1.52b)
RoCE = 25.87% (EBIT 615.0m / Capital Employed (Equity 1.52b + L.T.Debt 856.0m))
RoIC = 15.60% (NOPAT 423.8m / Invested Capital 2.72b)
WACC = 7.07% (E(3.77b)/V(4.90b) * Re(8.85%) + D(1.13b)/V(4.90b) * Rd(1.60%) * (1-Tc(0.31)))
Discount Rate = 8.85% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.63%
[DCF Debug] Terminal Value 80.10% ; FCFF base≈419.4m ; Y1≈375.1m ; Y5≈317.6m
Fair Price DCF = 116.1 (EV 6.96b - Net Debt 896.0m = Equity 6.06b / Shares 52.2m; r=7.07% [WACC]; 5y FCF grow -13.04% → 2.90% )
EPS Correlation: 42.19 | EPS CAGR: -2.62% | SUE: 1.28 | # QB: 1
Revenue Correlation: -83.88 | Revenue CAGR: -6.49% | SUE: -1.19 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.59 | Chg30d=-0.034 | Revisions Net=-1 | Analysts=4
EPS current Year (2026-09-30): EPS=6.58 | Chg30d=+0.105 | Revisions Net=+0 | Growth EPS=-9.3% | Growth Revenue=-3.4%
EPS next Year (2027-09-30): EPS=6.96 | Chg30d=-0.179 | Revisions Net=+0 | Growth EPS=+5.9% | Growth Revenue=+2.7%
P/E Forward = 10.9649
P/S = 1.0157
P/B = 2.4019
P/EG = 1.83
Revenue TTM = 3.61b USD
EBIT TTM = 615.0m USD
EBITDA TTM = 773.0m USD
Long Term Debt = 856.0m USD (from longTermDebt, last fiscal year)
Short Term Debt = 272.0m USD (from shortTermDebt, last quarter)
Debt = 1.13b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 896.0m USD (from netDebt column, last quarter)
Enterprise Value = 4.67b USD (3.77b + Debt 1.13b - CCE 230.0m)
Interest Coverage Ratio = 8.09 (Ebit TTM 615.0m / Interest Expense TTM 76.0m)
EV/FCF = 11.64x (Enterprise Value 4.67b / FCF TTM 401.0m)
FCF Yield = 8.59% (FCF TTM 401.0m / Enterprise Value 4.67b)
FCF Margin = 11.12% (FCF TTM 401.0m / Revenue TTM 3.61b)
Net Margin = 8.62% (Net Income TTM 311.0m / Revenue TTM 3.61b)
Gross Margin = 25.40% ((Revenue TTM 3.61b - Cost of Revenue TTM 2.69b) / Revenue TTM)
Gross Margin QoQ = 24.85% (prev 24.47%)
Tobins Q-Ratio = 1.24 (Enterprise Value 4.67b / Total Assets 3.76b)
Interest Expense / Debt = 1.60% (Interest Expense 18.0m / Debt 1.13b)
Taxrate = 31.09% (37.0m / 119.0m)
NOPAT = 423.8m (EBIT 615.0m * (1 - 31.09%))
Current Ratio = 1.67 (Total Current Assets 1.46b / Total Current Liabilities 874.0m)
Debt / Equity = 0.71 (Debt 1.13b / totalStockholderEquity, last quarter 1.57b)
Debt / EBITDA = 1.16 (Net Debt 896.0m / EBITDA 773.0m)
Debt / FCF = 2.23 (Net Debt 896.0m / FCF TTM 401.0m)
Total Stockholder Equity = 1.52b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.41% (Net Income 311.0m / Total Assets 3.76b)
RoE = 20.45% (Net Income TTM 311.0m / Total Stockholder Equity 1.52b)
RoCE = 25.87% (EBIT 615.0m / Capital Employed (Equity 1.52b + L.T.Debt 856.0m))
RoIC = 15.60% (NOPAT 423.8m / Invested Capital 2.72b)
WACC = 7.07% (E(3.77b)/V(4.90b) * Re(8.85%) + D(1.13b)/V(4.90b) * Rd(1.60%) * (1-Tc(0.31)))
Discount Rate = 8.85% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.63%
[DCF Debug] Terminal Value 80.10% ; FCFF base≈419.4m ; Y1≈375.1m ; Y5≈317.6m
Fair Price DCF = 116.1 (EV 6.96b - Net Debt 896.0m = Equity 6.06b / Shares 52.2m; r=7.07% [WACC]; 5y FCF grow -13.04% → 2.90% )
EPS Correlation: 42.19 | EPS CAGR: -2.62% | SUE: 1.28 | # QB: 1
Revenue Correlation: -83.88 | Revenue CAGR: -6.49% | SUE: -1.19 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.59 | Chg30d=-0.034 | Revisions Net=-1 | Analysts=4
EPS current Year (2026-09-30): EPS=6.58 | Chg30d=+0.105 | Revisions Net=+0 | Growth EPS=-9.3% | Growth Revenue=-3.4%
EPS next Year (2027-09-30): EPS=6.96 | Chg30d=-0.179 | Revisions Net=+0 | Growth EPS=+5.9% | Growth Revenue=+2.7%